Literature DB >> 29374076

PAD4 Deficiency Leads to Decreased Organ Dysfunction and Improved Survival in a Dual Insult Model of Hemorrhagic Shock and Sepsis.

Bethany M Biron1, Chun-Shiang Chung1, Yaping Chen1, Zachary Wilson1, Eleanor A Fallon1, Jonathan S Reichner1, Alfred Ayala2.   

Abstract

Indirect acute respiratory distress syndrome (iARDS) is caused by a nonpulmonary inflammatory process resulting from insults such as nonpulmonary sepsis. Neutrophils are thought to play a significant role in mediating ARDS, with the development of iARDS being characterized by dysregulation and recruitment of activated neutrophils into the lung. Recently, a novel mechanism of microbial killing by neutrophils was identified through the formation of neutrophil extracellular traps (NETs). NETs are composed of large webs of decondensed chromatin released from activated neutrophils into the extracellular space; they are regulated by the enzyme peptidylarginine deiminase 4 (PAD4) through mediation of chromatin decondensation via citrullination of target histones. Components of NETs have been implicated in ARDS. However, it is unknown whether there is any pathological significance of NET formation in ARDS caused indirectly by nonpulmonary insult. We subjected PAD4-/- mice and wild-type mice to a "two-hit" model of hypovolemic shock (fixed-pressure hemorrhage [Hem]) followed by septic cecal ligation and puncture (CLP) insult (Hem/CLP). Mice were hemorrhaged and resuscitated; 24 h after Hem, mice were then subjected to CLP. Overall, PAD4 deletion led to an improved survival as compared with wild-type mice. PAD4-/- mice displayed a marked decrease in neutrophil influx into the lung, as well decreased presence of proinflammatory mediators. PAD4-/- mice were also able to maintain baseline kidney function after Hem/CLP. These data taken together suggest PAD4-mediated NET formation contributes to the mortality associated with shock/sepsis and may play a role in the pathobiology of end organ injury in response to combined hemorrhage plus sepsis.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29374076      PMCID: PMC5821587          DOI: 10.4049/jimmunol.1700639

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  67 in total

1.  Citrullinated histone H3: a novel target for the treatment of sepsis.

Authors:  Yongqing Li; Zhengcai Liu; Baoling Liu; Ting Zhao; Wei Chong; Yanming Wang; Hasan B Alam
Journal:  Surgery       Date:  2014-06-21       Impact factor: 3.982

2.  Extracellular histones play an inflammatory role in acid aspiration-induced acute respiratory distress syndrome.

Authors:  Yanlin Zhang; Zongmei Wen; Li Guan; Ping Jiang; Tao Gu; Jinyuan Zhao; Xin Lv; Tao Wen
Journal:  Anesthesiology       Date:  2015-01       Impact factor: 7.892

3.  Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor.

Authors:  Alexander A Chumanevich; Corey P Causey; Bryan A Knuckley; Justin E Jones; Deepak Poudyal; Alena P Chumanevich; Tia Davis; Lydia E Matesic; Paul R Thompson; Lorne J Hofseth
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-03-17       Impact factor: 4.052

4.  Protein arginine deiminase 4: a target for an epigenetic cancer therapy.

Authors:  Jessica L Slack; Corey P Causey; Paul R Thompson
Journal:  Cell Mol Life Sci       Date:  2010-08-13       Impact factor: 9.261

5.  Incidence and outcomes of acute lung injury.

Authors:  Gordon D Rubenfeld; Ellen Caldwell; Eve Peabody; Jim Weaver; Diane P Martin; Margaret Neff; Eric J Stern; Leonard D Hudson
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

Review 6.  Acute lung injury and the acute respiratory distress syndrome: a clinical review.

Authors:  Arthur P Wheeler; Gordon R Bernard
Journal:  Lancet       Date:  2007-05-05       Impact factor: 79.321

Review 7.  Anti-citrulline antibodies in the diagnosis and prognosis of rheumatoid arthritis: evolving concepts.

Authors:  Amalia Raptopoulou; Prodromos Sidiropoulos; Maria Katsouraki; Dimitrios T Boumpas
Journal:  Crit Rev Clin Lab Sci       Date:  2007       Impact factor: 6.250

Review 8.  Advances in critical care for the nephrologist: acute lung injury/ARDS.

Authors:  Kathleen D Liu; Michael A Matthay
Journal:  Clin J Am Soc Nephrol       Date:  2008-01-16       Impact factor: 8.237

9.  BLOCKADE OF ENDOTHELIAL GROWTH FACTOR, ANGIOPOIETIN-2, REDUCES INDICES OF ARDS AND MORTALITY IN MICE RESULTING FROM THE DUAL-INSULTS OF HEMORRHAGIC SHOCK AND SEPSIS.

Authors:  Joanne L Lomas-Neira; Daithi S Heffernan; Alfred Ayala; Sean F Monaghan
Journal:  Shock       Date:  2016-02       Impact factor: 3.454

10.  Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation.

Authors:  Huw D Lewis; John Liddle; Jim E Coote; Stephen J Atkinson; Michael D Barker; Benjamin D Bax; Kevin L Bicker; Ryan P Bingham; Matthew Campbell; Yu Hua Chen; Chun-Wa Chung; Peter D Craggs; Rob P Davis; Dirk Eberhard; Gerard Joberty; Kenneth E Lind; Kelly Locke; Claire Maller; Kimberly Martinod; Chris Patten; Oxana Polyakova; Cecil E Rise; Martin Rüdiger; Robert J Sheppard; Daniel J Slade; Pamela Thomas; Jim Thorpe; Gang Yao; Gerard Drewes; Denisa D Wagner; Paul R Thompson; Rab K Prinjha; David M Wilson
Journal:  Nat Chem Biol       Date:  2015-01-26       Impact factor: 15.040

View more
  27 in total

Review 1.  The vitals of NETs.

Authors:  Chuyi Tan; Monowar Aziz; Ping Wang
Journal:  J Leukoc Biol       Date:  2020-12-30       Impact factor: 6.011

2.  Putative Roles for Peptidylarginine Deiminases in COVID-19.

Authors:  Elif Damla Arisan; Pinar Uysal-Onganer; Sigrun Lange
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

Review 3.  A Comparative Review of Neutrophil Extracellular Traps in Sepsis.

Authors:  Ronald H L Li; Fern Tablin
Journal:  Front Vet Sci       Date:  2018-11-28

4.  Cold-inducible RNA-binding Protein Induces Neutrophil Extracellular Traps in the Lungs during Sepsis.

Authors:  Yasumasa Ode; Monowar Aziz; Hui Jin; Adnan Arif; Jonathan G Nicastro; Ping Wang
Journal:  Sci Rep       Date:  2019-04-18       Impact factor: 4.379

Review 5.  Platelets and Intravascular Immunity: Guardians of the Vascular Space During Bloodstream Infections and Sepsis.

Authors:  Braedon McDonald; Mary Dunbar
Journal:  Front Immunol       Date:  2019-10-11       Impact factor: 7.561

6.  Inhibition of Efferocytosis by Extracellular CIRP-Induced Neutrophil Extracellular Traps.

Authors:  Kehong Chen; Atsushi Murao; Adnan Arif; Satoshi Takizawa; Hui Jin; Jianxin Jiang; Monowar Aziz; Ping Wang
Journal:  J Immunol       Date:  2020-12-30       Impact factor: 5.422

Review 7.  Neutrophils and COVID-19: Active Participants and Rational Therapeutic Targets.

Authors:  Jon Hazeldine; Janet M Lord
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

Review 8.  PAD4 takes charge during neutrophil activation: Impact of PAD4 mediated NET formation on immune-mediated disease.

Authors:  Xiaosong Liu; Tom Arfman; Kanin Wichapong; Chris P M Reutelingsperger; Jan Voorberg; Gerry A F Nicolaes
Journal:  J Thromb Haemost       Date:  2021-05-12       Impact factor: 5.824

9.  Peptidylarginine Deiminase 4 Promotes the Renal Infiltration of Neutrophils and Exacerbates the TLR7 Agonist-Induced Lupus Mice.

Authors:  Norio Hanata; Hirofumi Shoda; Hiroaki Hatano; Yasuo Nagafuchi; Toshihiko Komai; Tomohisa Okamura; Akari Suzuki; I Ketut Gunarta; Katsuji Yoshioka; Kazuhiko Yamamoto; Keishi Fujio
Journal:  Front Immunol       Date:  2020-06-23       Impact factor: 7.561

10.  Therapeutic ACPA inhibits NET formation: a potential therapy for neutrophil-mediated inflammatory diseases.

Authors:  Jos W G van Rosmalen; Maarten van der Linden; Renato G S Chirivi; Maximilien Euler; Gonny Schmets; Galina Bogatkevich; Konstantinos Kambas; Jonas Hahn; Quinte Braster; Oliver Soehnlein; Markus H Hoffmann; Helmuth H G van Es; Jos M H Raats
Journal:  Cell Mol Immunol       Date:  2020-03-20       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.